<strong>Objective</strong><strong>:</strong><span style="font-family:""><span style="font-family:Verdana;"> To compare between the efficacy of the use of or...<strong>Objective</strong><strong>:</strong><span style="font-family:""><span style="font-family:Verdana;"> To compare between the efficacy of the use of oral sildenafil plus low dose aspirin versus the use of oral low dose aspirin alone in pregnancy as preventive measure in women at risk for preeclampsia (PE). </span><b><span style="font-family:Verdana;">Design: </span></b><span style="font-family:Verdana;">A randomized clinical trial. </span><b><span style="font-family:Verdana;">Setting: </span></b><span style="font-family:Verdana;">Outpatient Obstetric clinic of Ain Shams University Maternity Hospital. </span><b><span style="font-family:Verdana;">Population or sample: </span></b><span style="font-family:Verdana;">Women at gestational age of </span></span><span style="font-family:""><span style="font-family:Verdana;">≤</span><span><span style="font-family:Verdana;">16 weeks who at risk for PE between June 2018 and June 2019. </span><b><span style="font-family:Verdana;">Methods:</span></b><span style="font-family:Verdana;"> Participants were randomly allocated into two groups: Group I Included 200 women who received a 25 mg tablet of oral sildenafil citrate tid until delivery plus 100 mg tablet of aspirin orally once daily until gestational age of 36 weeks, Group II Included 200 women who received a 100 mg tablet of aspirin orally once daily until gestational age of 36 weeks. </span><b><span style="font-family:Verdana;">Main Outcome Measures: </span></b><span style="font-family:Verdana;">Incidence of preeclampsia diagnosed per ACOG criteria. </span><b><span style="font-family:Verdana;">Results:</span></b><span style="font-family:Verdana;"> The incidence of PE in both groups showed no statistically significant difference. The incidence of PE in the first group is 11.0%, and it is 12.0% in the second group (p-value 0.754). </span><b><span style="font-family:Verdana;">Conclusion:</span></b><span style="font-family:Verdana;"> The addition of sildenafil citrate to low dose aspirin had no impact on the prevention of展开更多
目的:探讨超声评分法在胎盘植入性疾病(placenta accr eta spectr um,PAS)严重程度预测中的应用价值。方法:收集2020年1月1日至2022年6月30日彭水苗族土家族自治县中医院妇产科收治的100例疑似PAS的孕产妇作为研究对象。对其均进行超声...目的:探讨超声评分法在胎盘植入性疾病(placenta accr eta spectr um,PAS)严重程度预测中的应用价值。方法:收集2020年1月1日至2022年6月30日彭水苗族土家族自治县中医院妇产科收治的100例疑似PAS的孕产妇作为研究对象。对其均进行超声检查,对比超声评分法与“金标准”(手术探查)在诊断PAS、初步诊断PAS严重程度、诊断不同严重程度PAS上的差异,从多个角度评估术前超声评分法诊断PAS的临床价值。结果:在诊断孕产妇是否存在PAS上,术前超声评分法与“金标准”之间无明显差异(P=0.687);在初步诊断孕产妇不同严重程度PAS(粘连、植入和穿透)上,术前超声评分法与“金标准”的一致性良好(Kappa值为0.880,P<0.001);术前超声评分法对诊断不同严重程度PAS的准确性不同,对PAS-2、PAS-3、PAS-6的诊断具有高准确性,对PAS-4、PAS-5的诊断具有较高的准确性,对PAS-6的诊断准确性最高(AUC=0.881)。总体上,超声评分法诊断PAS具有高准确性(P<0.05)。结论:超声评分法对PAS的严重程度具有良好的临床预测价值,但在诊断不同严重程度PAS方面存在一定的差异。展开更多
文摘<strong>Objective</strong><strong>:</strong><span style="font-family:""><span style="font-family:Verdana;"> To compare between the efficacy of the use of oral sildenafil plus low dose aspirin versus the use of oral low dose aspirin alone in pregnancy as preventive measure in women at risk for preeclampsia (PE). </span><b><span style="font-family:Verdana;">Design: </span></b><span style="font-family:Verdana;">A randomized clinical trial. </span><b><span style="font-family:Verdana;">Setting: </span></b><span style="font-family:Verdana;">Outpatient Obstetric clinic of Ain Shams University Maternity Hospital. </span><b><span style="font-family:Verdana;">Population or sample: </span></b><span style="font-family:Verdana;">Women at gestational age of </span></span><span style="font-family:""><span style="font-family:Verdana;">≤</span><span><span style="font-family:Verdana;">16 weeks who at risk for PE between June 2018 and June 2019. </span><b><span style="font-family:Verdana;">Methods:</span></b><span style="font-family:Verdana;"> Participants were randomly allocated into two groups: Group I Included 200 women who received a 25 mg tablet of oral sildenafil citrate tid until delivery plus 100 mg tablet of aspirin orally once daily until gestational age of 36 weeks, Group II Included 200 women who received a 100 mg tablet of aspirin orally once daily until gestational age of 36 weeks. </span><b><span style="font-family:Verdana;">Main Outcome Measures: </span></b><span style="font-family:Verdana;">Incidence of preeclampsia diagnosed per ACOG criteria. </span><b><span style="font-family:Verdana;">Results:</span></b><span style="font-family:Verdana;"> The incidence of PE in both groups showed no statistically significant difference. The incidence of PE in the first group is 11.0%, and it is 12.0% in the second group (p-value 0.754). </span><b><span style="font-family:Verdana;">Conclusion:</span></b><span style="font-family:Verdana;"> The addition of sildenafil citrate to low dose aspirin had no impact on the prevention of
文摘目的:探讨超声评分法在胎盘植入性疾病(placenta accr eta spectr um,PAS)严重程度预测中的应用价值。方法:收集2020年1月1日至2022年6月30日彭水苗族土家族自治县中医院妇产科收治的100例疑似PAS的孕产妇作为研究对象。对其均进行超声检查,对比超声评分法与“金标准”(手术探查)在诊断PAS、初步诊断PAS严重程度、诊断不同严重程度PAS上的差异,从多个角度评估术前超声评分法诊断PAS的临床价值。结果:在诊断孕产妇是否存在PAS上,术前超声评分法与“金标准”之间无明显差异(P=0.687);在初步诊断孕产妇不同严重程度PAS(粘连、植入和穿透)上,术前超声评分法与“金标准”的一致性良好(Kappa值为0.880,P<0.001);术前超声评分法对诊断不同严重程度PAS的准确性不同,对PAS-2、PAS-3、PAS-6的诊断具有高准确性,对PAS-4、PAS-5的诊断具有较高的准确性,对PAS-6的诊断准确性最高(AUC=0.881)。总体上,超声评分法诊断PAS具有高准确性(P<0.05)。结论:超声评分法对PAS的严重程度具有良好的临床预测价值,但在诊断不同严重程度PAS方面存在一定的差异。
